
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
Supplemental tables for the above-mentioned article, providing additional information about the application of operational excellence methods.
about 18 years ago
Biomanufacturing Capacity Quandaryabout 18 years ago
Applying Operational Excellence Concepts to Biopharmaceutical Processingabout 18 years ago
Contract Manufacturing in India: Is the CMO Model a Viable Business?about 18 years ago
The Environmental Impact of Disposablesabout 18 years ago
Top 10 Legal Issues Biotech Start-Ups Must Addressabout 18 years ago
The Challenges and Benefits of Disposable Technologiesabout 18 years ago
Statistical Essentials—Part 4: Regression and Design of Experimentsabout 18 years ago
The Company at the Crossroads. Part 2: Build or Buy?





